Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial
Dong‐Wan Kim(Seoul National University Hospital), Ranee Mehra(Fox Chase Cancer Center), Daniel S.W. Tan(National Cancer Centre Singapore), Enriqueta Felip, Laura Q.M. Chow(University of Washington), D. Ross Camidge(University of Colorado Denver), Johan Vansteenkiste(KU Leuven), Sunil Sharma(Huntsman Cancer Institute), Tommaso De Pas(European Institute of Oncology), Gregory J. Riely(Memorial Sloan Kettering Cancer Center), Benjamin Solomon(Peter MacCallum Cancer Centre), Jürgen Wolf(University Hospital Cologne), Michael Thomas(University Hospital Heidelberg), Martin Schüler(Deutschen Konsortium für Translationale Krebsforschung), Geoffrey Liu(Princess Margaret Cancer Centre), Armando Santoro(Istituti di Ricovero e Cura a Carattere Scientifico), Santosh Sutradhar(Novartis (United States)), Siyu Li(Novartis (United States)), Tomasz Szczudlo(Novartis (United States)), A. Yovine(Novartis (Switzerland)), Alice T. Shaw(Massachusetts General Hospital)
Cited by 470Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis